Mycophenolatmofetil Hexal (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolatmofetil Hexal, is an antimetabolite immunosuppressant presented as an oral formulation for systemic use. It is used to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis.

GNH USA supplies Mycophenolatmofetil Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is employed in immunosuppressive regimens targeting organ transplantation and autoimmune disorders.

- Organ transplant rejection prevention: reduces the risk of acute and chronic graft rejection. - Lupus nephritis: improves renal outcomes in patients with systemic lupus erythematosus. - Other autoimmune conditions (off‑label): may be used in selected cases of vasculitis or dermatomyositis under specialist supervision.

Adverse reactions can vary in frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhoea, or abdominal pain. - Haematologic changes: leukopenia, anaemia, or thrombocytopenia. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Headache or dizziness. - Elevated liver enzymes.

Serious or Rare Side Effects: - Severe infections such as opportunistic or reactivating viruses. - Progressive multifocal leukoencephalopathy (PML). - Life‑threatening bone marrow suppression. - Malignancies, particularly post‑transplant lymphoproliferative disorder. - Severe hypersensitivity reactions including Stevens‑Johnson syndrome. - Pregnancy‑related teratogenicity (Category X).

Patients and prescribers should consider several safety measures before and during therapy.

- Pregnancy: contraindicated in pregnancy (Category X); effective contraception is required. - Breastfeeding: not recommended as the drug is excreted in milk. - Renal impairment: dose adjustment may be needed; monitor renal function regularly. - Hepatic dysfunction: assess liver enzymes before initiation and periodically thereafter. - Infection risk: screen for latent infections (e.g., TB, hepatitis B) and vaccinate appropriately before starting. - Store at ambient temperature: keep below 25 °C, retain in the original container, and protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce drug absorption; separate dosing by at least 2 hours. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly decrease exposure and may lead to graft rejection. - Live vaccines: increased risk of severe infection; avoid concurrent use.

Moderate Interactions (Monitor Closely): - Azathioprine or other myelosuppressants: additive bone‑marrow suppression; monitor blood counts. - ACE inhibitors or ARBs: may exacerbate renal dysfunction; assess renal function. - High‑dose steroids: may increase infection risk; observe clinical signs closely.